title: Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home.
abstract: This study describes antipsychotic use and metabolic monitoring rates among individuals with developmental disabilities enrolled in a subspecialty medical home (N = 826). Four hundred ninety-nine participants (60.4 %) were taking antipsychotics, which was associated with male gender (p = 0.01), intellectual disability with and without autism spectrum disorder (p = 0.001 and p = 0.04, respectively), and inversely associated with the youngest and oldest age categories (p = 0.001 and p = 0.04, respectively). Among those taking antipsychotics, annual metabolic monitoring rates ranged from 89 % (lipids) to 99 % (weight). Age was positively associated with glucose (p < 0.001) and lipid monitoring (p < 0.001). Adult participants with dyslipidemia (p < 0.01), prediabetes/diabetes (p = 0.04), and hypertension (p = 0.02) were significantly more likely to obtain lipid monitoring. These values exceeded previously reported rates suggesting the importance of an integrated care model.
authors.affiliation: Department of Psychiatry, University of Utah, 650 Komas Drive, Suite 200, Salt Lake City, UT, 84108, USA. Lisa.ruiz@hsc.utah.edu.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Ruiz
authors.affiliation: University of Utah, 650 Komas Drive, Suite 200, Salt Lake City, UT, 84108, USA.
authors.forename: Mackenzie
authors.initials: M
authors.lastname: Damron
authors.affiliation: Department of Family and Preventive Medicine, University of Utah, 650 Komas Drive, Suite 200, Salt Lake City, UT, 84108, USA.
authors.forename: Kyle B
authors.initials: KB
authors.lastname: Jones
authors.affiliation: Department of Psychiatry, University of Utah, 650 Komas Drive, Suite 200, Salt Lake City, UT, 84108, USA.
authors.forename: Dean
authors.initials: D
authors.lastname: Weedon
authors.affiliation: Department of Pediatrics, University of Utah, 650 Komas Drive, Suite 200, Salt Lake City, UT, 84108, USA.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Carbone
authors.affiliation: Department of Psychiatry, University of Utah, 650 Komas Drive, Suite 200, Salt Lake City, UT, 84108, USA.
authors.forename: Amanda V
authors.initials: AV
authors.lastname: Bakian
authors.affiliation: Department of Psychiatry, University of Utah, 650 Komas Drive, Suite 200, Salt Lake City, UT, 84108, USA.
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Bilder
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000067877:Autism Spectrum Disorder / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D008484:Medicaid; D008875:Middle Aged; D018802:Patient-Centered Care; D012737:Sex Factors; D014481:United States; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D008055:Lipids
keywords: Antipsychotics; Autism spectrum disorder; Intellectual disability; Medical home
references.citation: Ment Health Fam Med. 2012 Sep;9(3):137-48
references.pmid: 23997820
references.citation: Lancet. 1989 Mar 4;1(8636):495
references.pmid: 2563862
references.citation: Arch Intern Med. 2003 May 12;163(9):1077-83
references.pmid: 12742806
references.citation: J Child Adolesc Psychopharmacol. 2005 Feb;15(1):116-26
references.pmid: 15741793
references.citation: Am J Psychiatry. 2003 Feb;160(2):284-9
references.pmid: 12562574
references.citation: Psychiatry Res. 2001 Apr 15;101(3):277-88
references.pmid: 11311931
references.citation: Psychiatr Danub. 2012 Sep;24(3):314-22
references.pmid: 23013638
references.citation: J Autism Dev Disord. 2013 Mar;43(3):719-31
references.pmid: 22829245
references.citation: BMC Psychiatry. 2009 Dec 18;9:80
references.pmid: 20021664
references.citation: J Intellect Disabil Res. 2008 Apr;52(Pt 4):287-98
references.pmid: 18339091
references.citation: J Health Care Poor Underserved. 2012 Nov;23(4):1600-8
references.pmid: 23698674
references.citation: J Intellect Disabil. 2013 Sep;17(3):223-35
references.pmid: 23801356
references.citation: J Intellect Disabil Res. 2011 Jul;55(7):665-74
references.pmid: 21507097
references.citation: Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51
references.pmid: 20368487
references.citation: J Psychiatr Ment Health Nurs. 2012 Jun;19(5):389-94
references.pmid: 22070226
references.citation: Acta Psychiatr Scand. 2008 Jul;118(1):26-33
references.pmid: 18582345
references.citation: Br J Psychiatry. 2011 Oct;199(4):289-95
references.pmid: 21816867
references.citation: JAMA. 2007 Jul 18;298(3):309-16
references.pmid: 17635891
references.citation: Schizophr Res. 2011 Mar;126(1-3):117-23
references.pmid: 21168994
references.citation: JAMA. 2007 Jul 18;298(3):299-308
references.pmid: 17635890
references.citation: Am J Psychiatry. 2009 Mar;166(3):345-53
references.pmid: 19147694
references.citation: J Autism Dev Disord. 2014 Dec;44(12):3063-71
references.pmid: 24958436
references.citation: Psychol Med. 2012 Jan;42(1):125-47
references.pmid: 21846426
references.citation: J Clin Psychiatry. 2004 Feb;65(2):267-72
references.pmid: 15003083
references.citation: J Am Pharm Assoc (2003). 2008 May-Jun;48(3):393-400
references.pmid: 18595825
references.citation: Pediatrics. 2012 Nov;130 Suppl 2:S69-76
references.pmid: 23118256